Post-Doc: Preclinical development of monoclonal antibodies for the treatment of AL cardiac amyloidosis- ON-431

Discipline(s) souhaitée: Biochimie / biologie moléculaire, Sciences de la vie, Biologie, Médecine, Microbiologie / immunologie, Mathématiques, Sciences mathématiques
Entreprise: Paradox Immunotherpeutics
Durée du projet: 6 months to 1 year
Preferred start date: As soon as possible.
Langue exigée: English
Emplacement(s): Toronto, Canada; Canada
Nombre de postes: 1
Rechercher dans les réseaux internationaux de Mitacs - cochez cette case si vous souhaitez recevoir des profils de chercheurs basés à l’extérieur du Canada: 
No

Au sujet de l’entreprise: 

Paradox Immunotherapeutics is a Toronto-based pharmaceutical company developing immunotherapies for rare diseases that cause organ failure. Using a proven-successful immunotherapy drug design platform, they design drugs that harness the body’s own immune system to clear lethal deposits from affected organs and reverse organ damage. Their current research pipeline includes a potential treatment for immunoglobulin light chain (AL) cardiac amyloidosis, another cause of heart failure for which no first-line therapy currently exists and a US market opportunity of ~$3.2B.With a team of experts in immunotherapy drug design, they possess an orphan drug discovery platform for the potential treatment of ~30 rare diseases, a platform technology which has already sparked the interest of major players in the pharmaceutical industry.

Veuillez décrire le projet.: 

This project is seeking a postdoctoral fellow to work with Dr. Avi Chakrabartty at the University of Toronto.

Amyloid cardiomyopathy is an under-recognized cause of heart failure and is caused by normal proteins in the bloodstream going bad (known as amyloid) and accumulating in the heart. This accumulation of amyloid in the heart tissue causes the wall of the heart to become rigid and ineffective at pumping blood to the rest of the body, causing heart failure. We are studying a form of amyloid cardiomyopathy called immunoglobulin light chain (AL) amyloidosis, caused by the accumulation of light chain proteins. AL amyloidosis can also affect organs other than the heart and cause life-threatening multi-organ failure. We have designed a drug to potentially treat AL amyloidosis. The drug works by tagging these amyloid and harness the power of the immune system to recruit the body's own immune cells to clear these amyloid from the organs, restoring organ function. This project involves screening our drugs for safety and effectiveness in mice. as well as drug characterization before it can be used in humans.

Expertise ou compétences exigées: 

  • Protein expression & biochemistry/immunoassay development
  • PhD in biochemistry, biological sciences, or related discipline
  • Demonstrated experience with immunoassays, antibody purification, BLI/SPR, affinity binding assays or flow cytometry is preferred
  • Able to conduct experiments, analyze data and perform troubleshooting without supervision when needed
  • Quick learner, entrepreneurial spirit and work ethic